How to Get Zepbound Without Insurance in 2026
Zepbound's list price is $1,059 per month, but almost no one pays that. The legitimate cash-pay paths bring it down to roughly $299–$299/month in July 2026, ranked by typical cost. Eli Lilly's LillyDirect self-pay vials are usually the cheapest path.
Cash-pay Zepbound paths at a glance
| Path | Monthly | Annual |
|---|---|---|
| Zepbound Savings Card (with commercial insurance) | ~$25 | ~$300 |
| Compounded tirzepatide via telehealth | $299 | $3,588 |
| LillyDirect self-pay vials (2.5 / 5 mg) | $299 | $3,588 |
| Branded Zepbound via telehealth | $499 | $5,988 |
| Cash retail (full WAC) | $1,059 | $12,708 |
1. Zepbound Savings Card (if you have commercial insurance)
If your commercial insurance covers Zepbound but the copay is high, the manufacturer Savings Card from Eli Lilly typically reduces the copay to around $25/month. If your commercial insurance does NOT cover Zepbound, the SAME card offers a separate path: KwikPen at $299 to $449 per month dose-dependent. Most patients do not know about the second path.
Full eligibility, limits, and the two distinct paths on the Zepbound Coupon page. See also the cross-drug GLP-1 Savings Cards comparison.
2. LillyDirect self-pay vials ($299/mo, lower doses)
LillyDirect is Eli Lilly's direct-to-consumer storefront. The Zepbound vial product (currently 2.5 mg and 5 mg starting doses) is priced around $299 per month - a steep discount versus the auto-injector pen WAC of $1,059. The trade-off is a manual syringe draw rather than a pre-filled pen.
Higher doses (7.5 mg, 10 mg, 12.5 mg, 15 mg) are not in the LillyDirect self-pay vial menu. If you titrate above 5 mg and want to stay self-pay, the path is branded telehealth or, where legal, compounded tirzepatide.
Visit LillyDirect →3. Compounded tirzepatide (~$299/mo, narrow eligibility)
Legal availability narrowed once the FDA closed the shortage-based exemption in early 2025 - only patients with a documented individual clinical need (non-standard dose, allergy) now qualify under a 503A pharmacy's individual-patient exception; cost savings alone does not. Where still available, pricing runs around $299/mo. See the full compounded GLP-1 regulatory timeline and pharmacy-verification checklist before ordering.
4. Branded Zepbound via telehealth (~$499/mo)
If LillyDirect doses don't fit and compounded isn't available, branded Zepbound through telehealth typically runs around $499 per month including the prescriber visit and shipping.
Major options:
Affiliate partners listed below - your price does not change.
- Hims & Hers - fast onboarding, in-house pharmacy
- Ro - Body Program with coaching included
- Lemonaid Health - pay per visit
- LifeMD - wide GLP-1 menu
See our full telehealth provider comparison.
5. Run the comparison vs Wegovy and Mounjaro
Zepbound is usually the best $/lb-lost cash-pay GLP-1 because of its 22.5% peak weight loss in SURMOUNT-1 versus ~14.9% for Wegovy and lower for off-label Mounjaro. Run the math directly:
- Wegovy vs Zepbound - head-to-head
- Cheapest GLP-1 finder - all 8 drugs ranked
- How to Get Wegovy Without Insurance - parallel guide for the semaglutide side
- How to Get Mounjaro Without Insurance - the diabetes-brand version of the same molecule
- Tirzepatide Cost (Every Channel) - molecule-level guide across Mounjaro, Zepbound, and compounded
Frequently asked questions
How much does Zepbound cost without insurance in 2026?
Zepbound is uniquely positioned versus every other GLP-1 without insurance because Eli Lilly split it into two distinct product formats to hit different cash-pay tiers. LillyDirect self-pay vials (a manual syringe draw, not a prefilled pen) start at $299/mo for the 2.5 mg starter dose, $399/mo for 5 mg, and $449/mo for 7.5, 10, 12.5, and 15 mg - all within a 45-day refill window. The prefilled autoinjector pens are pharmacy-only at close to WAC ($1,059/mo). The trade-off Lilly explicitly markets is "syringe draw, not autoinjector convenience, in exchange for a lower cash-pay floor." The Zepbound Savings Card is a separate mechanism that only reduces copay when commercial insurance already covers the drug. Compounded tirzepatide narrowed sharply after the FDA officially ended the tirzepatide shortage in late 2024. Zepbound's SURMOUNT-1 primary endpoint is a 22.5% peak weight loss at 72 weeks - the highest of any FDA-approved GLP-1 as of July 2026, which is why the per-pound-lost math on Zepbound tends to win even when monthly cost is comparable.
What is LillyDirect and what does it offer for Zepbound?
LillyDirect is Eli Lilly's direct-to-consumer self-pay program. As of July 2026, it sells Zepbound vials (lower doses, 2.5 mg and 5 mg) starting around $299 per month. The auto-injector pen versions are not in the LillyDirect self-pay menu - they are only available through pharmacies under insurance or full WAC pricing. The vial format requires a manual draw with a syringe, which Lilly explicitly markets as the trade-off for the lower price.
Is the Zepbound savings card the same as LillyDirect?
No - they are two different programs from Eli Lilly. The Zepbound Savings Card reduces copay (often to ~$25) for patients whose commercial insurance already covers Zepbound. LillyDirect self-pay is for patients without coverage and is priced separately. Government insurance - Medicare, Medicaid, Tricare, VA - is excluded from the savings card by federal anti-kickback rules, but those patients can still use LillyDirect self-pay.
Is compounded tirzepatide still available in 2026?
For Zepbound specifically, the legal picture on compounded tirzepatide is more open than for semaglutide - but the practical availability is still narrower than 2023–2024. Tirzepatide was declared "resolved" from the FDA shortage list in late 2024, ending the §503A shortage exemption that allowed mass compounding for any patient at any dose. Personalized compounded tirzepatide is still legal when produced by a licensed 503A pharmacy for a documented individual clinical need - e.g. a prescriber-specified excipient, a non-standard dose escalation, or a dose not commercially available. As of July 2026 state posture varies: some state boards of pharmacy have specifically restricted routine 503A tirzepatide compounding, others have not. Because Zepbound already has a dedicated LillyDirect vial program starting at $299/mo - the cheapest legitimate cash-pay tirzepatide - compounded is rarely the right call for a routine Zepbound self-pay case. It matters most for patients who cannot tolerate the commercial formulation.
Should I switch from Wegovy to Zepbound to save money?
Often yes, on cost-per-pound-lost basis. Zepbound trial efficacy is ~22.5% peak weight loss in SURMOUNT-1 versus ~14.9% for Wegovy in STEP-1, and the LillyDirect self-pay floor for Zepbound is comparable to or below NovoCare for Wegovy. So even when Zepbound costs slightly more per month, you tend to lose more weight per dollar. The /wegovy-vs-zepbound-guide page runs this side-by-side.
Does Mounjaro cash-pay save more than Zepbound?
Usually no, in 2026. Mounjaro (same molecule as Zepbound, FDA-approved for type 2 diabetes) does not have an equivalent of LillyDirect self-pay vials. Off-label cash-pay Mounjaro typically runs at full WAC or telehealth pricing, which is higher than Zepbound's LillyDirect floor. The exception: if you have type 2 diabetes and your insurance covers Mounjaro but not Zepbound, the diabetes-channel copay is the cheapest path.
Can I use a GoodRx coupon on Zepbound?
Coupons rarely beat LillyDirect or telehealth pricing. Zepbound is brand-name and patent-protected, so retail pharmacy cash prices are close to WAC even with coupons. GoodRx Care's telehealth subscription ($39/month) plus the pharmacy cost is occasionally competitive, but for most users LillyDirect self-pay is the cheaper path.
Zepbound coverage by major insurer
Coverage stance and per-carrier details for Zepbound. Each link goes to the full prior-auth requirements, cost table, and appeal playbook for that carrier.
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.